Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study. [electronic resource]
Producer: 20181012Description: 3235-3244 p. digitalISSN:- 1349-7006
- Aged
- Aged, 80 and over
- Aniline Compounds -- pharmacokinetics
- Creatine Kinase -- blood
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- Female
- Humans
- Japan -- epidemiology
- Leukemia, Myeloid, Acute -- blood
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Recurrence, Local -- blood
- Protein Kinase Inhibitors -- pharmacokinetics
- Proto-Oncogene Proteins -- antagonists & inhibitors
- Pyrazines -- pharmacokinetics
- Receptor Protein-Tyrosine Kinases -- antagonists & inhibitors
- Thrombocytopenia -- chemically induced
- Treatment Outcome
- fms-Like Tyrosine Kinase 3 -- antagonists & inhibitors
- Axl Receptor Tyrosine Kinase
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.